VBL Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Merger with Notable expected to close in late September or October, subject to VBL's S-4 registration statement being declared effective and shareholder approval $24.3 million in cash and cash equivalents as of June 30,